CHRS: Coherus Oncology, Inc. Common Stock Company Profile & Statistics

Coherus Oncology, Inc. Common Stock Profile

About

Coherus is a fully integrated commercial-stage innovative oncology company. Coherus, formerly known as Coherus BioSciences Inc., is based in REDWOOD CITY, Calif.

Info & Links

CEO

Dennis M. Lanfear

Headquarters

333 TWIN DOLPHIN DRIVE, SUITE 600
REDWOOD CITY, CA 94065, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

306

Coherus Oncology, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization²

156.91M

Enterprise Value

-23.12M

Enterprise Value/EBITDA(ttm)

0.26

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

1.10

Price to Book(mrq)

1.31

Price to Cash(ytd)

4.63

Profitability

Gross Margin(ttm)

62.93%

Operating Margin(ttm)

-107.66%

Profit Margin(ttm)

529.17%

Return on Equity(ttm)

Return on Invested Capital(ttm)

29.36%

Return on Assets(ttm)

-34.85%

Income Statement

Revenue(ttm)

272.21M

Revenue Per Share(ttm)

2.34

Gross Profit(ttm)

151.86M

EBITDA(ttm)³

-90.53M

Net Income Available to Common(ttm)

179.75M

Diluted EPS(ttm)

1.55

Share Statistics

Beta (5Y Monthly)

0.88

52-Week Change

4.23%

S&P 500 52-Week Change

17.28%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

116.23M

Dividend Yield

0.00%

Float⁴

106.84M

% Held by Insiders

8.08%

% Held by Institutions

72.82%

Balance Sheet

Total Cash(mrq)

237.64M

Total Cash Per Share(mrq)

2.04

Total Debt(mrq)

36.87M

Total Debt/Equity(mrq)

30.77%

Current Ratio(mrq)

1.44%

Quick Ratio(mrq)

1.43%

Book Value Per Share(mrq)

1.03

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.62

Free Cash Flow(ytd)

-72.46M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

CHRS

Coherus Oncology, Inc. Common Stock